STAGE IV PROSTATE CANCER AJCC V8

This study is for men with prostate cancer that has spread to other parts of the body. It compares standard drug therapy alone versus standard therapy plus either surgery to remove the prostate or radiation to the prostate. The goal is to see if adding local treatment helps patie…

This study tests whether a precise, short-course radiation therapy (SBRT) works as well as a slightly longer radiation approach (hypofractionated radiotherapy) for men whose prostate cancer has returned or spread to a few spots after surgery. About 118 participants will receive o…

This study tests whether giving a drug called abemaciclib before a targeted radiation therapy (177Lu-PSMA-617) can make the radiation work better for men with advanced prostate cancer that has stopped responding to other treatments. About 30 participants will receive the combinat…

This study is testing a drug called talazoparib in people with advanced solid tumors that have specific DNA repair gene mutations. The goal is to see if this PARP inhibitor can shrink tumors or slow their growth, even in patients who have already tried a similar drug. About 36 ad…

This study tests a radioactive drug called lutetium Lu 177 dotatate in 30 people with a rare and aggressive form of prostate cancer that has spread. The drug seeks out and delivers radiation directly to cancer cells that have certain markers. The goal is to see if it can shrink t…

This study tests whether adding the drug talazoparib to standard hormone therapy can better control prostate cancer that still responds to hormone treatment. About 70 men with metastatic prostate cancer will receive the combination. The goal is to see if this approach lowers PSA …

This study tests whether taking a hormone-blocking drug (relugolix) for a few days before a PSMA PET/CT scan can make prostate cancer cells more visible. The goal is to improve detection of cancer that has spread to lymph nodes in men with high-risk prostate cancer. About 30 part…

This study compares the side effects of two standard treatments for advanced prostate cancer: abiraterone plus prednisone versus darolutamide alone. About 75 men with prostate cancer that has spread will take one of these medications. The goal is to see which treatment causes few…

This study looks at whether giving cancer therapy at home instead of in a clinic can improve the experience for Black men with advanced prostate cancer. About 38 participants will try both home and clinic treatments to compare safety, side effects, and satisfaction. The goal is t…

This study tests whether using bright white light therapy glasses can reduce fatigue and improve mood in men with advanced prostate cancer who are on hormone therapy. About 210 men will either start light therapy right away or wait a few months. The goal is to help patients feel …

This study tests whether adding cryoablation (freezing cancer cells) to standard radiation therapy provides better pain relief for people with cancer that has spread to the bones. About 40 adults with certain advanced cancers (like prostate, kidney, or colorectal) will be enrolle…

This study looks at whether having a trained peer navigator—someone who guides patients through the process—helps African American men with advanced prostate cancer better understand and complete genetic testing. Genetic testing is important for treatment decisions, but many Afri…

This study looks at how common low vitamin D levels are in African American men with prostate cancer, and whether correcting those levels can improve immune function. Researchers will measure vitamin D and immune cells in blood samples before and after supplementation. The goal i…